Jan 21bioAnalytics launches HeartFriendly™ Dentist Program with the Dental Health Group of Burlington Using Biosign UFIT® Health Monitor
Jan. 21, 2011 (PR Newswire) --
TORONTO - Biosign Technologies Inc. (TSXV: BIO) and bioAnalytics Inc. announced today that the Dental Health Group in Burlington, Ontario, has deployed the HeartFriendly Dentist™ program, which utilizes the UFIT®TEN-10 Health Monitor.
"Our mandate for the HeartFriendly™ Dentist program is to support patient health and help improve vital sign testing in dental care," stated Steve Colivas, President of bioAnalytics. "This testing may assist dentists in detecting abnormal vital signs, such as high blood pressure and irregular pulse, and in referring patients to physicians as needed. We believe the UFIT®TEN-10, utilized at the point of care, will eventually become a standard tool for every dental clinic and assist in improving overall patient health".
Dentists are well-positioned to screen patients for hypertension and other health conditions before providing dental treatment. Under the HeartFriendly™ Dentist program, dental professionals use UFIT® TEN-10 to conduct a 60- second reading similar to that using a blood pressure cuff. Test results include blood pressure statistics (systolic, diastolic, and mean arterial pressure "MAP")) as well as pulse rate average and variability. In addition, the UFIT®TEN-10 provides a real-time tracing of the arterial pressure pulse. Dentists can use this comprehensive information to better monitor the overall health of their patients.
"Currently, our Dental Health Group services the dental needs of approximately 11,000 Burlington-area residents. We have approximately 30 clinical staff who use the UFIT® TEN-10 to routinely take vital signs of patients in our practice", stated Dr. Christian von Rosenbach, one of the founding partners at Dental Health Group. "In this day and age, when so many people are suffering from hypertension and other chronic heart diseases, we have a responsibility to monitor our patients' health. The Biosign UFIT® TEN-10 device gives us an excellent tool with which we can assess a patient's cardiovascular status at the time of treatment."
"The HeartFriendly™ Dentist program represents a substantial opportunity for us to introduce Biosign's UFIT® services to over 65,000 dental professionals and to the 23 million Canadians that consult them annually," stated Peter Tassiopoulos, CEO of Biosign. "This program also demonstrates how UFIT® supports segment-focused approaches to the market."
About bioAnalytics Inc.
bioAnalytics has developed the HeartFriendly™ Dentist program to provide leading-edge, medical devices to dental professionals, allowing them to measure and monitor their patients' vital signs easily, reliably, and routinely. Please visit
www.heartfriendlydentist.com
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit
www.biosign.com.
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release